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Abstract
Background: We have followed-up on the recent genome-wide association (GWA) of the clusterin gene (CLU)
with increased risk for Alzheimer disease (AD), by performing an unbiased resequencing of all CLU coding exons
and regulatory regions in an extended Flanders-Belgian cohort of Caucasian AD patients and control individuals (n
= 1930). Moreover, we have replicated genetic findings by targeted resequencing in independent Caucasian
cohorts of French (n = 2182) and Canadian (n = 573) origin and by performing meta-analysis combining our data
with previous genetic CLU screenings.
Results: In the Flanders-Belgian cohort, we identified significant clustering in exons 5-8 of rare genetic variations
leading to non-synonymous substitutions and a 9-bp insertion/deletion affecting the CLU b-chain (p = 0.02).
Replicating this observation by targeted resequencing of CLU exons 5-8 in 2 independent Caucasian cohorts of
French and Canadian origin identified identical as well as novel non-synonymous substitutions and small insertion/
deletions. A meta-analysis, combining the datasets of the 3 cohorts with published CLU sequencing data,
confirmed that rare coding variations in the CLU b-chain were significantly enriched in AD patients (ORMH = 1.96
[95% CI = 1.18-3.25]; p = 0.009). Single nucleotide polymorphisms (SNPs) association analysis indicated the
common AD risk association (GWA SNP rs11136000, p = 0.013) in the 3 combined datasets could not be explained
by the presence of the rare coding variations we identified. Further, high-density SNP mapping in the CLU locus
mapped the common association signal to a more 5’ CLU region.
Conclusions: We identified a new genetic risk association of AD with rare coding CLU variations that is
independent of the 5’ common association signal identified in the GWA studies. At this stage the role of these
coding variations and their likely effect on the b-chain domain and CLU protein functioning remains unclear and
requires further studies.
Keywords: Alzheimer disease, clusterin gene (CLU), genomic resequencing, non-synonymous substitutions, inser-
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Genome-wide association (GWA) studies lead to long-
awaited breakthroughs in the genetics of late-onset Alz-
heimer disease (AD) [MIM 104300] [1] by providing
conclusive genetic association evidence for novel AD
risk genes [2-5]. Notably, GWA significance with similar
effect sizes was reached for the top single nucleotide
polymorphism (SNP) rs11136000 in the clusterin gene
(CLU) [MIM 185430] [1]. The CLU protein (also known
as apolipoprotein J) is a multifunctional protein showing
functional similarities with the major apolipoprotein of
the brain, apolipoprotein E (APOE) [6]. In relation to
AD, CLU expression is increased in pyramidal neurons
and astrocytes of the hippocampus and entorhinal cor-
tex, the most severely affected brain regions in AD [7].
CLU is present in senile plaques [8], binds to Ab and is
involved in Ab42 clearance across the blood brain barrier
[9]. Moreover, CLU enhances endocytosis of Ab aggre-
gates to brain phagocytes [10]. Taking its variety of phy-
siological functions, CLU could be a guardian or enemy
in AD [11].
The CLU transcriptional unit is located in the chro-
mosomal region 8p21-p12 and comprises 9 exons in the
longest transcript that translates in the main CLU pro-
tein isoform of a 449 amino-acid residues. The CLU
precursor peptide is internally cleaved to produce an a-
and b-subunit, held together by disulphide bridges and
is subsequently secreted from the cell (Figure 1)[12].
In this follow-up study aiming at identifying the
genetic variant underlying the CLU association with
increased AD risk, we examined the CLU genetic varia-
bility using a resequencing approach including all cod-
ing exons and regulatory regions in a well-documented
Flanders-Belgian patient/control cohort (n = 1930 sub-
jects) [2,3]. Significant genetic findings were verified by
targeted resequencing in two independently ascertained
French [3] and Canadian [13] AD cohorts and by meta-
analyses of the genetic data sets generated in this study
with published data sets obtained of previous genetic
screenings of CLU in AD cohorts [14,15].
Results
CLU resequencing
The stage I resequencing of the coding exons and the
regulatory regions of CLU in patients and control indivi-
duals of the Flanders-Belgian AD cohort (n = 1930)
(Table 1), identified in total 19 rare to intermediate rare
non-synonymous single nucleotide variations predicting
an amino acid substitution in the CLU protein of which
only 5 had been reported earlier [14,15] (Table 2).
Further, we detected an in-frame 9-bp deletion predict-
ing a 3 amino acid deletion p.T445_D447del. Fourteen
of the 19 non-synonymous substitutions occurred in 31
AD patients (n = 849, 3.6%), of which 8 appeared only
in patients (n = 11), and 6 in patients (n = 20) and con-
trol individuals (n = 20). One AD patient carried 2 non-
synonymous substitutions p.R338W and p.T345M, and
one healthy individual carried both p.S16R and p.
R234H. All 3 AD patients with p.T445_D447del carried
also p.A309T. The remaining 5 non-synonymous substi-
tutions occurred only in control individuals (n = 5), add-
ing up to 25 control carriers (n =6 5 9 ,3 . 8 % )( T a b l e2
Figure 1).
Seven of the 14 non-synonymous substitutions
observed in patients were predicted to have a possible
or probable harmful effect on CLU protein structure
and function using physical and comparative considera-
tions embedded in the PolyPhen software [16](Table 2).
SIFT software [17,18] assessing whether the amino acid
substitutions had an effect on CLU protein function
based on evolutionary conservation identified 3 non-tol-
erated substitutions (p.R338W, p.S16R and p.H37Q)
(Table 2) (Figure 1). For 4 patients carrying a rare non-
synonymous CLU variant, we obtained positive disease
history data. In their pedigree, we identified only one
other affected first degree relative which suggested that
Table 1 Description of cohorts.
Stage I: Flanders-Belgian AD
cohort
Stage II: Lille AD
cohort
Stage II: Toronto AD
cohort
Stage III: Caribbean Hispanic AD
cohort
Total number of subjects 1930 2182 573 1045
AD patients 1057 1465 323 520
Mean AAO (years) (SD) 74.9 ± 8.9 69.5 ± 8.2 75.3 ± 9.7 79.7 ± 8.6
Women (%) 692 (65.5) 969 (66.1) 178 (55.1) 369 (71.0)
At least one APOE ε4
allele (%)
565 (53.5) 852 (58.2) 182 (56.3) 207 (39.9)
Control individuals 873 717 250 525
Mean AAI (years) (SD) 65.1 ± 14.9 74.0 ± 8.0 73.0 ± 10.2 78.9 ± 6.5
Women (%) 501 (57.4) 447 (62.3) 149 (60.0) 358 (68.2)
At least one APOE ε4
allele (%)
235 (26.9) 145 (20.2) 60 (24.0) 126 (24.0)
AAO = age at onset; SD = standard deviation; AAI = age at inclusion.
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penetrance.
In contrast, all 5 non-synonymous substitutions
detected only in control individuals were labeled by
PolyPhen software as benign and were tolerated accord-
ing to SIFT software (Table 2 Figure 1).
Genetic variations in regulatory elements were also
detected in AD patients but none of these genetic var-
iants were located within conserved transcription factor
binding sites (See table part D in Additional file 1). In
addition, no CLU variants were found affecting splicing
using FSPLICE, Netgene2 and SPL prediction programs
(See table part E in Additional file 1).
Association analyses of rare CLU variants
Though overall the percentages of CLU rare variant car-
riers among AD patients and control individuals was
similar, visible inspection of the distribution of the non-
synonymous substitutions in AD patients suggested
clustering in exons 5-8 which for the most part are cod-
ing for the CLU b-chain domain (Table 2) (Figure 1).
Statistical analysis confirmed significant clustering in
exons 5-8 with 3.8 times more carriers of non-synon-
ymous substitutions or a deletion mutation among
patients than control individuals (p =0 . 0 2 ) .T oc o n f i r m
this observation, we used targeted resequencing of
exons 5-8 in two independent replication AD cohorts of
Table 2 Rare non-synonymous CLU variants identified in Stage I Flanders-Belgium AD cohort.
Stage I: Flanders-Belgium AD cohort
Gene
location
a
DNA
b Protein
c dbSNP Total
number
MAF
AD
MAF
C
Protein location PolyPhen
(PSIC)
SIFT
Exon 5 c.924G > A p.A309T 3 0.0018
(1)
b-chain benign (1.07) tolerated (0.65)
Exon 6 c.1012C > T p.R338W 2 0.0012
(2)
b-chain probable (2.37) not tolerated
(0.00)
Exon 6 c.1034C > T p.T345M 1 0.0006
(2)
b-chain possible (1.56) tolerated (0.09)
Exon 7 c.1105A > C p.N369H rs9331936 2 0.0012 b-chain possible (1.56) tolerated (0.15)
Exon 7 c.1138G > A p.D380N rs9331938 1 0.0006 b-chain benign (0.32) tolerated (0.36)
Exon 7 c.1319C > T p.T440M 1 0.0006 b-chain possible (1.75) not tolerated
(0.01)
Exon 8 c.1333_1341del p.
T445_D447
del
3 0.0018
(1)
b-chain
Exon 8 c.1343C > T p.S448L rs13494 1 0.0006 b-chain benign (0.73) tolerated (0.23)
Exon 8 c.1349T > G p.V450G 1 0.0006 b-chain benign (1.42) tolerated (0.15)
Exon 1 c.48C > A p.S16R 11 0.0029
(5 AD)
0.0046
(6 C)
(3)
extra AA isoform
2
benign (1.13) not tolerated
(0.00)
Exon 1 c.111C > A p.H37Q 4 0.0012
(2 AD)
0.0015
(2 C)
extra AA isoform
2
possible (1.80) not tolerated
(0.00)
Exon 5 c.701G > A p.R234H 3 0.0012
(2 AD)
0.0008
(1 C)
(3)
a-chain possible (1.64) tolerated (0.15)
Exon 5 c.764C > T p.T255I rs4127629 11 0.0029
(5 AD)
0.0046
(6 C)
a-chain benign (0.31) tolerated (0.29)
Exon 5 c.965T > C p.P322L 9 0.0029
(5 AD)
0.0030
(4 C)
b-chain possible (1.96) tolerated (0.25)
Exon 7 c.1153G > A p.V385I 3 0.0006
(1 AD)
0.0015
(2 C)
b-chain benign (0.15) tolerated (0.40)
Exon 5 c.703G > A p.A235T 1 0.0008 a-chain benign (1.18) tolerated (0.16)
Exon 5 c.797G > A p.R266Q 1 0.0008 a-chain benign (0.27) tolerated (0.67)
Exon 6 c.994G > A p.D332N 1 0.0008 b-chain benign (0.04) tolerated (0.1)
Exon 7 c.1268G > A p.R423Q 1 0.0008 b-chain benign (0.33) tolerated (0.54)
Exon 7 c.1298A > C p.Q433P 1 0.0008 b-chain benign (0.41) tolerated (0.13)
aGene location position according to the longest CLU transcript with 9 coding exons [NM_001831.2],
bNumbering according to CLU mRNA sequence starting at
the A of the ATG translation initation codon in the reference sequence [GenBank accesion number NM_001831.2],
cNumbering according to CLU protein
sequence [GenPept accession number NP_001822.2]; MAF = Minor Allele Frequency, calculated upon the minimum number of successful sequences (1698
patient and 1318 control alleles);
(1) 3 AD patients carry 2 different CLU variants
(2) 1 AD patient with 2 CLU variants
(3) 1 control individual with 2 CLU variants.
Prediction of pathogenicity of missense mutations was performed using in silico programs PolyPhen (benign/possibly damaging/probably damaging) and SIFT
(tolerated/not tolerated).
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tified non-synonymous CLU substitutions of which p.
R338W, p.N369H and insertion/deletion p.
T445_D447del that were already observed in Flanders-
Belgian patients. Also, in the Lille AD cohort one 1 bp-
insertion predicted a frameshift and premature stop
codon - p.I303NfsX13 was found in one AD patient
(Table 3) (Figure 1).
Allele sharing among p.T445_D447del carriers i.e. 3
Flanders-Belgian, 3 French, 1 Canadian patients and off-
spring of two Belgian patients was examined by geno-
typing short tandem repeat markers located in a 1.3 Mb
region of the CLU locus (See table in Additional file 2).
DNA available of two children (non-affected, inclusion
ages < 50 years) allowed to reconstruct phased haplo-
types. No other family members were available. The 3
Flanders-Belgian patients shared alleles at 10 neighbor-
ing markers constituting a haplotype of 1.3 Mb around
CLU. Seven of these consecutive markers were shared
by 2 French patients. A third French patient and a
Canadian patient carrier shared 3 markers of this haplo-
type near CLU. Of note, only Flanders-Belgian patients
also carried non-synonymous variant p.A309T.
All non-synonymous substitutions and the deletion/
insertion mutations observed in the 3 AD cohorts affecting
the CLU b-chain domain were carried forward in a meta-
analysis (Table 4). Similarly, we included in the meta-ana-
lysis previously reported non-synonymous substitutions
that were observed in Portuguese, UK and US Caucasian
AD cohorts [14,15]. Combining the information of in total
6724 patient and 4820 control chromosomes, the meta-
analysis confirmed that non-synonymous substitutions
and insertion/deletions in exons 5-8 were significantly
more enriched in AD patients compared to healthy con-
trol individuals (ORMH 1.96 [95% CI 1.18-3.25]; pMH =
0.009, pwoolf = 0.551) (Table 4).
To assess whether the mutation frequencies of rare
coding variants differed by ethnicity, we also rese-
quenced exons 5-8 in a Caribbean Hispanic AD patient/
control cohort (Table 5). This identified 2 novel benign
non-synonymous substitutions affecting the CLU b-
chain domain - p.E431Q and p.D331N. In addition, 3
non-synonymous substitutions found in Belgian, French
and Canadian individuals were more frequently observed
in Caribbean Hispanics - p.N369H, p.D380N and p.
S448L (Table 5) (Figure 1).
Table 3 Rare non-synonymous CLU variants identified in Stage II Lille and Toronto AD cohorts.
Stage II: Lille AD cohort
Gene
location
a
DNA
b Protein
c dbSNP Total
number
MAF
AD
MAF
C
Protein
location
PolyPhen
(PSIC)
SIFT
Exon 5 c.908insA p.I303NfsX13 1 0.0004 b-chain
Exon 6 c.1012C > T p.R338W 1 0.0004 b-chain probable (2.37) not tolerated
(0.00)
Exon 7 c.1105A > C p.N369H rs9331936 6 0.0023 b-chain possible (1.56) tolerated (0.15)
Exon 8 c.1333_1341del p.
T445_D447del
3 0.0011 b-chain
Exon 8 c.1343C > T p.S448L rs13494 1 0.0004 b-chain benign (0.73) tolerated (0.23)
Exon 8 c.1358G > A p.G453S rs34627536 1 0.0004 b-chain benign (0.39)
Exon 5 c.965T > C p.P322L 5 0.0015
(4 AD)
0.0008
(1 C)
b-chain possible (1.96) tolerated (0.25)
Exon 7 c.1138G > A p.D380N rs9331938 5 0.0015
(4 AD)
0.0008
(1 C)
b-chain benign (0.32) tolerated (0.36)
Exon 7 c.1310G > A p.R437Q 1 0.0008 b-chain benign (0.700)
Stage II: Toronto AD cohort
Gene
location
a
DNA
b Protein
c dbSNP Total
Number
MAF
AD
MAF
C
Protein
location
PolyPhen
(PSIC)
SIFT
Exon 7 c.1138G > A p.D380N rs9331938 1 0.0016 b-chain benign (0.322) tolerated (0.36)
Exon 8 c.1333_1341del p.
T445_D447del
1 0.0016 b-chain
Exon 7 c.1105A > C p.N369H rs9331936 3 0.0033
(2 AD)
0.0022
(1 C)
b-chain possibly (1.557) tolerated (0.15)
Exon 8 c.1343C > T p.S448L rs13494 3 0.0033
(2 AD)
0.0022
(1 C)
b-chain benign (0.73) tolerated (0.23)
aGene location position according to the longest CLU transcript with 9 coding exons [NM_001831.2],
bNumbering according to CLU mRNA sequence starting at
the A of the ATG translation initation codon in the reference sequence [GenBank accesion number NM_001831.2],
cNumbering according to CLU protein
sequence [GenPept accession number NP_001822.2]; MAF = Minor Allele Frequency, calculated upon the minimum number of successful sequences (Lille cohort:
2650 patient and 1214 control alleles; Toronto cohort: 608 patient and 462 control alleles). Prediction of pathogenicity of missense mutations was performed
using in silico programs PolyPhen (benign/possibly damaging/probably damaging) and SIFT (tolerated/not tolerated).
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Page 4 of 12Figure 1 Schematic location of rare CLU coding variants identified in stage I, II and III resequencing. (A) Schematic presentation of CLU
gene structure, CLU transcript 1 [NM_001831.2] and CLU protein [NP_001822.2]. Coding variants observed in AD patients only are indicated in
red, variants observed in patients and controls in blue, variants detected in control individuals only in green. All predicted pathogenic variants
are indicated in bold. After cleavage of the signal peptide, the secreted CLU form (449 AA) contains two coiled-coiled domains (pink), three
amphipathic domains (blue) and a cysteine rich region (yellow) with 5 disulfide bridges (grey). Six N-glycosylation sites are marked in purple. For
ease of interpretation, amino acids are given for specific CLU domains and for detected protein variants only. (B) Conservation alignment of
amino acids of CLU beta-chain variants is shown in different species; Homo sapiens (ENSP00000315130), Gorilla gorilla (ENSGGOP00000016521),
Pan troglodytes (ENSPTRP00000034423), Pongo abelii (ENSPPYP00000020696), Macaca mulata (ENSMMUP0000003216), Nomascus leucogenys
(ENSNLEP00000020015), Tarsius syrichta (ENSTSYP00000001230), Mus musculus (ENSMUSP00000022616), Rattus norvegicus
(ENSRNOP00000022095), Canis lupus familiaris (ENSCAFP00000012350) and Bos taurus (ENSBTAP00000007324). Similar to panel A, patient specific
variants are marked in red, variants observed in patients and controls in blue and variants in control individuals in green. All predicted
pathogenic variants are marked in bold.
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We analyzed association in the Flanders-Belgian AD
cohort with the GWA top SNP rs11136000 and 14
other SNPs in the CLU locus, aiming at replicating the
common AD risk association with CLU as well as fine-
mapping the common association signal. We observed
significant allelic association with rs11136000 (p =
0.004) and 4 other SNPs (p < 0.05) (Table 6a). Stratifica-
tion by APOE ε4 genotype indicated that allelic associa-
tions were only significant in the APOE ε4+s t r a t u m
(See table in Additional file 3). All five SNPs are posi-
tioned within the same LD block (D’ between 0.12 and
1.00, r
2 between 0.00 and 0.96) (See figure in Additional
file 4 and table in Additional file 5). Conditional logistic
regression analysis showed that the 4 associated SNPs
were not independent from GWA top SNP rs11136000
(data not shown).
Next, we genotyped the 5 associated SNPs in the Lille
and Toronto AD cohorts and calculated allelic associa-
tion with AD risk (Table 6a). Nominal significance was
observed in the Lille AD cohort with 4 out of 5 SNPs
and in the APOE ε4+ stratum of the Lille AD cohort
with rs9331908 (p = 0.024) (See table in Additional file
6). In the Toronto cohort association was only signifi-
cant in the APOE ε4+ stratum with rs867230 (p =
0.024) and rs7982 (p = 0.023) (See table in Additional
file 6).
Meta-analysis combining data from all 3 AD cohorts,
confirmed allelic association with GWA SNP
rs11136000 (p = 0.013), but showed the strongest asso-
ciation after Bonferroni correction with rs1532278 (p=
0.005) (Table 6b, figure in Additional file 7).
Next, we investigated whether the significantly
increased presence of rare non-synonymous
Table 4 Meta-analysis of rare CLU genetic variants.
Total chromosome
number
Rare genetic variants
AD C AD (%) C (%) OR [95% CI]
Flanders-Belgian (this study) 1698 1318 21 (1.2) 9 (0.7) 1.82 [0.8-3.39]
Lille (this study) 2610 1220 21 (0.8) 3 (0.2) 3.29 [0.98-11.05]
Toronto (this study) 612 462 6 (1.0) 2 (0.4) 2.28 [0.46-11.33]
Portugal (Guerreiro et al.)
14 806 470 9 (1.1) 2 (0.4) 2.64 [0.57-12.28]
UK (Guerreiro et al.)
14 892 1264 2 (0.2) 2 (0.2) 1.42 [0.20-10.09]
US-Caucasian (Tycko et al.)
15 106 86 1 (0.9) 3 (3.5) 0.26 [0.03-2.58]
Summary 6724 4820 60 (0.9) 21 (0.4) 1.96 [1.18-3.25]
pMH = 0.009
pwoolf = 0.551
Total allele counts and frequencies of rare non-synonymous substitutions affecting the CLU b-chain observed in AD patients and control individuals. P-values are
given for fixed-effect Mantel-Haenszel test (pMH) and Woolf’s test for heterogeneity (pwoolf). Odds ratios are given with 95% confidence intervals; summary odds
ratio is based on a fixed-effect Mantel-Haenszel meta-analysis. Significant associations are depicted in bold. Compared to our p.R338W finding, Guerreiro and
colleagues
14 observed another non-synonymous substitution at codon 338 in 1 AD patient 5 (p.R338Q).
Table 5 Rare non-synonymous CLU variants identified in Stage III Caribbean Hispanic AD cohort.
Stage III: Caribbean Hispanic AD cohort
Gene location
a DNA
b Protein
c dbSNP Total number MAF AD MAF C Protein location PolyPhen (PSIC) SIFT
Exon 5 c.965T > C p.P322L 2 0.0022 b-chain possible (1.96) tolerated (0.25)
Exon 6 c.991G > A p.D331N 2 0.0022 b-chain benign (0.119) tolerated (0.28)
Exon 7 c.1291G > C p.E431Q 1 0.0011 b-chain benign (0.133) tolerated (0.35)
Exon 7 c.1105A > C p.N369H* rs9331936 155 0.08
(84 AD)
0.07
(71 C)
b-chain possible (1.56) tolerated (0.00)
Exon 7 c.1138G > A p.D380N* rs9331938 35 0.01
(13 AD)
0.02
(22 C)
b-chain benign(0.32) tolerated (0.36)
Exon 8 c.1343C > T p.S448L* rs13494 27 0.01
(13 AD)
0.01
(14 C)
b-chain benign(0.73) tolerated (0.23)
Exon 6 c.1004C > T p.T335I 1 0.0010 b-chain benign (1.077) tolerated (0.64)
Exon 7 c.1153G > A p.V385I 1 0.0010 b-chain benign (0.150) tolerated (0.4)
aGene location position according to the longest CLU transcript with 9 coding exons [NM_001831.2],
bNumbering according to CLU mRNA sequence starting at
the A of the ATG translation initation codon in the reference sequence [GenBank accesion number NM_001831.2],
cNumbering according to CLU protein
sequence [GenPept accession number NP_001822.2]; MAF = Minor Allele Frequency, calculated upon the minimum number of successful sequences. (Caribbean
Hispanic cohort: 926 patient and 974 control alleles), * = 3 non-synonymous variants with intermediate frequencies (MAF = 1-5%) in patients and control
individuals. Prediction of pathogenicity of missense mutations was performed using in silico programs PolyPhen (benign/possibly damaging/probably damaging)
and SIFT (tolerated/not tolerated).
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could have driven the common association of CLU with
AD risk. Hereto, we recalculated the allelic association
in the meta-analysis after excluding the 58 carriers from
the Flanders-Belgian (26), the Lille (24) and the Toronto
(8) AD cohorts. Allelic associations with the 5 common
SNPs remained significant (p-values < 0.05), indicating
that the associations with the common SNPs and the
rare coding variations represent two independent obser-
vations (data not shown).
Discussion
We used an extensive resequencing approach to follow-
up on the significant association of common SNPs in
the CLU locus with increased risk for AD in 2 indepen-
dent GWA studies. In the discovery stage, we used
unbiased resequencing of all coding and regulatory
regions of CLU in a Flanders-Belgian AD cohort fol-
lowed by targeted sequencing of 2 independent replica-
tion cohorts of French and Canadian origin. In the
Flanders-Belgian AD cohort, we obtained significant
Table 6 Common CLU associations with AD.
(A) Allelic associations in stage I and II AD cohorts
Belgian-Flanders Lille Toronto
Allele AD (total) C
(total)
OR [95% CI] p AD
(total)
C
(total)
OR [95% CI] p AD
(total)
C
(total)
OR [95%
CI]
p
rs867230 T 0.63 (1259) 0.59
(952)
0.074
(1)
0.66
(1736)
0.62
(742)
0.022
(1)
0.60
(367)
0.63
(307)
0.288
(1)
Intron 1 G 0.37 (752) 0.41
(670)
0.82 [0.70-0.96] 0.012
(2)
0.34
(904)
0.38
(456)
0.89 [0.76-1.04] 0.144
(2)
0.40
(247)
0.37
(181)
1.04
[0.80-1.36]
0.771
(2)
rs1532278 G 0.63 (1308) 0.61
(1006)
< 0.01
(1)
0.675
(1789)
0.628
(764)
0.004
(1)
0.62
(383)
0.62
(301)
0.996
(1)
Intron 3 A 0.37 (770) 0.40
(656)
0.83 [0.71-0.97] 0.019
(2)
0.325
(861)
0.372
(452)
0.83 [0.71-0.97] 0.02
(2)
0.38
(233)
0.38
(183)
1.27
[0.97-1.64]
0.078
(2)
rs11136000 G 0.65 (1232) 0.61
(990)
0.034
(1)
0.66
(1707)
0.628
(764)
0.195
(1)
0.61
(372)
0.63
(299)
0.645
(1)
Intron 3 A 0.35 (676) 0.39
(630)
0.79 [0.68-0.93] 0.004
(2)
0.34
(875)
0.372
(452)
0.93 [0.79-1.10] 0.400
(2)
0.39
(236)
0.37
(179)
1.00
[0.77-1.31]
0.986
(2)
rs9331908 G 0.66 (1389) 0.69
(1161)
0.055
(1)
0.62
(1712)
0.66
(841)
0.036
(1)
0.66
(416)
0.69
(338)
0.297
(1)
Intron 4 A 0.34 (713) 0.31
(521)
1.18 [1.01-1.39] 0.035
(2)
0.38
(1046)
0.35
(443)
1.12 [0.96-1.30] 0.156
(2)
0.34
(214)
0.31
(152)
1.20
[0.91-1.56]
0.198
(2)
rs7982 C 0.63 (1228) 0.61
(1005)
0.191
(1)
0.67
(1780)
0.63
(804)
0.022
(1)
0.62
(374)
0.60
(295)
0.434
(1)
Exon 5 T 0.37 (734) 0.40
(657)
0.85 [0.73-0.99] 0.037
(2)
0.33
(884)
0.37
(470)
0.89 [0.76-1.03] 0.124
(2)
0.38
(234)
0.36
(167)
1.16
[0.89-1.52]
0.273
(2)
(B) Meta-analysis of stage I and II AD cohorts
Allele Summary OR pMH pBonf pwoolf’
rs867230 T
Intron 1 G 0.88 [0.79-0.97] 0.013 0.065 0.311
rs1532278 G
Intron 3 A 0.85 [0.77-0.94] 0.001 0.005 0.648
rs11136000 G
Intron 3 A 0.88 [0.79-0.97] 0.013 0.065 0.206
rs9331908 G
Intron 4 A 1.16 [1.04-1.28] 0.006 0.030 0.824
rs7982 C
Exon 5 T 0.89 [0.80-0.98] 0.023 0.115 0.448
(A) Allele frequencies are shown with absolute numbers in brackets.
(1) The first p-value is the 2-sided p-value of the unadjusted c
2 statistics,
(2) The second p-
value is adjusted for age, APOE status and gender. Calculations of odds ratios (OR), presented with 95% confidence intervals (CI), were performed using the
common allele as reference allele. (B) For meta-analysis, Mantel-Haenszel summary OR ratios are given with 95% CI and corresponding p-values (pMH) based on
fixed-effects meta-analysis of age, gender and APOE- adjusted effect estimates of the minor allele. Nominal p-values (pmh, adjusted for age, gender and APOE
effects) and Bonferroni corrected p-values (p Bonf) for the number of SNPs (N = 5) in the meta-analysis are given. P-values of Woolf’s test for heterogeneity (p-
woolf) are given.
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5 to 8, predicting 3 possible (p.T345M, p.N369H, p.
T440M) and one probable (p.R338W) damaging non-
synonymous substitutions and a 9-bp insertion/deletion
p.T445_D447del affecting the CLU b-chain domain.
Interestingly, 4 AD patients carried multiple CLU varia-
tions: a patient with a positive family history and onset
age of 68 years harbored 2 predicted pathogenic substi-
tutions (p.R338W, p.T345M) and three patients carried
the deletion p.T445_D447del together with the benign
variant p.A309T. Targeted resequencing in the Lille and
Toronto AD cohorts identified predicted pathogenic
substitutions (p.R338W and p.N369H) in French AD
patients and the p.T445_D447del deletion in French and
Canadian AD patients. Noteworthy, we observed haplo-
type sharing with 7 markers around the insertion/dele-
tion site in 3 Belgian and 2 French AD patient carriers
which is suggestive for a common ancestor. Partial hap-
lotype sharing was further observed with another French
and Canadian patient.
Moreover, we identified a 1-bp insertion/deletion var-
iation p.I303NfsX13, predicting a premature stop codon
after 315 amino acid residues (24 of which in b-chain),
in a French patient (onset age 68 years). This frame-
shift mutation would most likely produce an unstable
transcript that is degraded by the nonsense mediated
mRNA decay control system or an unstable C-truncated
protein that is degraded within the cell, however, no
patient material was available for further testing. Substi-
tutions p.R338W and p.T345M are positioned inside the
disulphide rich region which is involved in the folding
of the a and b-domains into a heterodimer complex.
Variant p.N369H deletes a CLU N-glycosylation signal
[19], and since CLU is highly glycosylated (20-25% of its
total mass comprises carbohydrates), this substitution
might affect CLU processing or functioning in ligand
interaction. Although absent from all Belgian and
French control individuals (> 2500 control chromo-
somes), p.N369H was present in one Canadian control
person aged 58 years, which is suggestive of an inter-
mediate penetrance for this substitution. We also
observed 3 non-synonymous substitutions with possible
damaging effects (a-chain and b-chain) in both Flan-
ders-Belgian patients and control individuals. As these
variants were found in 1 to 4 control individuals only
and the control group had on average a younger inclu-
sion age than the patient group, these substitutions
might represent risk factors of intermediate disease
penetrance and might still contribute to AD risk. In
contrast, all non-synonymous substitutions observed in
control individuals were predicted to be benign and to
unlikely affect CLU protein functioning, strengthening
our observation that rare non-synonymous substitutions
might contribute to AD risk.
Meta-analysis including all rare coding variants affect-
ing the CLU b-chain domain observed in the discovery
and replication cohorts plus those reported in 3 addi-
tional cohorts [14,15], totaling 5772 patients and con-
trols, lent further support to an increased occurrence of
rare coding variants predicted to affect the CLU b-chain
in AD patients compared to healthy individuals (ORMH
1.96 [95% CI 1.18-3.25]; p = 0.009). Assessing the preva-
lence of variations affecting the b-chain domain by tar-
geted resequencing of CLU exons 5 to 8 in a Caribbean
Hispanic AD cohort, detected novel benign variants
while predicted pathogenic variants found in stage I and
II AD cohorts were absent. Of note, predicted patho-
genic variant p.N369H was more frequently observed in
Hispanic patient and control individuals then in stage I
and II Caucasian cohorts, suggesting this variant might
be a polymorphism which is in agreement with previous
reports in African-Americans [15]. Excluding p.N369H
from our meta-analysis on rare variants did not alter the
significance of our observation that rare coding variants
affecting the CLU b-chain are more frequently observed
in AD patients than control individuals (p = 0.001). It is
possible that rare CLU variants contribute in a different
way to disease risk in diverse populations and alterna-
tively, that part of the genetic CLU variability is popula-
tion-specific (e.g. Hispanic origin). Screening other and
larger AD cohorts of different ethnicity and conducting
functional analyses on putative pathogenic variants will
help unraveling the role of these rare coding variants to
AD risk. In this context it is relevant to mention that
we have primarily used protein prediction algorithms
that have their limitations as well. While our meta-ana-
lysis suggested that the CLU b-chain is involved in AD
risk, to adequately discriminate between rare or low fre-
quent pathogenic variants and benign polymorphisms,
their pathogenicity needs to be experimentally evaluated.
These experiments will have to be performed along with
c o m p a r a b l ee f f o r t sa i m i n ga tu n d e r s t a n d i n gt h er o l eo f
CLU in AD pathogenesis.
Although we identified an association of AD risk with
clustering of rare coding variants affecting the CLU b
chain, this association was independent from the asso-
ciation with rs11136000, the top GWA SNP [2,3]. Geno-
typing rs11136000 in the stage I and II cohorts followed
by a meta- analysis showed significant association (p =
0.013). This association remained significant after exclu-
sion of carriers with predicted pathogenic b-chain var-
iants. This is in line with recent LRRK2 observations in
which independent common risk associations were
found after exclusion of carriers with known pathogenic
mutations [20]. Further, high-density association fine-
mapping by genotyping common SNPs throughout the
CLU locus in the stage I cohort, identified 4 additional
SNP associations, that all except one (rs9331908) were
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2 > 0.89) and located in
the 5’ CLU region. This association region ranges from
CLU intron 1 to exon 5, which is only marginally over-
lapping with the rare variant association region in the b-
chain (exon 5 to 8). Combined with the two indepen-
dent association signals for common and rare CLU var-
iants, this could imply two distinct mechanisms
underlying AD risk.
Further genotyping of the 4 significant SNPs and com-
bined meta-analyses on all 3 AD cohorts showed, after
Bonferroni correction, the strongest evidence of associa-
tion with rs1532278 (p = 0.005). This variant is located
in an intron 3 sequence that strongly resembles a regu-
latory element based on sequence alignment of seven
species. Also, association evidence was found for
rs867230 in CLU intron 1, which potentially affects a
MEF2 transcription factor binding site. These two novel
associated common variants may represent variants of
functional relevance underlying the common association
signal with rs11136000 in various populations [21-23].
In agreement with other reports [14,21], we did not
observe any association with common coding variants.
Though we did not find association with the recently
described splice site variant rs9331888 [24] in our Flan-
ders-Belgian population (OR 1.11 [95% CI 0.94-1.31]; p
= 0.2), our association findings do point to common
variants with possible regulatory effects (rs1532278,
rs867230). It is likely that a number of common and
rare CLU variants contribute to an increased risk for
AD. In addition, different mechanisms may contribute
to disease: our common CLU associations might regu-
late CLU transcription while our rare CLU association
signal results from non-synonymous variants affecting
protein functioning. Whether these rare CLU variants
represent loss or gain of function variants remains at
present unclear and requires further studies.
Conclusions
In conclusion, in-depth CLU resequencing showed sig-
nificant clustering and association of rare coding var-
iants with AD risk in a combined meta-analysis of 3
Caucasian AD cohorts analyzed in this study and
cohorts of previous published studies. The rare coding
variants are non-synonymous substitutions and inser-
tion/deletion mutations that affect the CLU b-chain
domain. While the physiological properties of the b-
chain domain remain unclear, our data suggests that
this protein subunit may be of interest in AD pathogen-
esis, and merits follow-up with detailed functional ana-
lyses. Also, in our combined AD data set, the rare
coding variant association was independent of the com-
mon AD risk association signal that we fine-mapped to
am o r e5 ’ region of CLU. The strongest association was
not obtained with GWA SNP rs11136000 but with an
intron 3 SNP (rs1532278) located in a sequence with
high regulatory potential. Altogether, our data suggest
that CLU may be a risk gene in which multiple rare and
common variants have independent effects on AD dis-
ease susceptibility.
Methods
AD cohorts
Flanders-Belgian AD cohort
In the stage I analysis, we used as discovery sample an
extended Flanders-Belgian AD cohort of 1930 subjects.
A fraction of this AD cohort (n = 1750, 91%) contribu-
ted to the replication phase of the 2 AD GWA studies
confirming AD risk association at the CLU locus [2,3].
Since then we extended the AD cohort dataset with
newly ascertained subjects and additional genotypes.
The AD patients have been ascertained at memory
clinics and neurology divisions in a prospective study of
neurodegenerative and vascular dementia in Flanders,
the Dutch-speaking region of Belgium [25,26], and in a
comparable prospective study on molecular genetics of
cognitive impairment [27] using the same clinical assess-
ments and biosampling schemes (Table 1). Each AD
patient underwent a neuropsychological examination,
including Mini-Mental State Examination (MMSE)[28]
and structural and/or functional neuroimaging [27].
Consensus diagnosis of possible or probable AD was
obtained by minimal two neurologists based on the
National Institute of Neurological and Communication
Disorders and Stroke-Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRDA) criteria [29].
Unrelated control individuals had no neurological or
psychiatric antecedents or had neurological complaints
or organic disease involving the central nervous system.
Additional community control individuals were included
after interview concerning medical and family history
and a Mini Mental State Examination (MMSE) > 24
[28].
French and Canadian AD cohorts
In the stage II analysis, we used two independent Cau-
casian AD patient/control cohorts for replication of rare
coding variants in CLU exons 5-8 by targeted resequen-
cing. A first French AD cohort consisted of patients
ascertained in the North of France (Lille AD cohort)
that were diagnosed with probable AD according to
DSM-III-R and NINCDS/ADRDA criteria. Healthy con-
trol individuals were from the same geographical area
and were cognitively intact, had no family history of AD
or DSM-III-R criteria for dementia and a MMSE ≥ 25
(Table 1) [30,31]. In a second Canadian AD cohort
(Toronto AD cohort [13]), diagnoses of probable or pos-
s i b l eA Dw e r ed e f i n e da c c o r d i n gt ot h eN I N C D S -
ADRDA criteria at clinics specialized in memory disor-
ders [29]. Subjects were classified as control individuals
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dementia at last visit (Table 1) [32].
Caribbean Hispanic AD cohort
In the stage III analysis, we initiated an assessment of
the contribution of rare coding CLU variants in popula-
tions of different ethnicity by analyzing an AD cohort of
Caribbean Hispanics ancestry for rare coding mutations
by resequencing CLU exons 5-8 (Table 1). The diagnosis
of AD was based on the NINCDS/ADRDA criteria
[29,33].
Ethical assurances
All clinical and genetic studies described in this manu-
script were approved by the medical ethical committees
of the respective hospital divisions and university genetic
laboratories at the respective cohort sampling sites in
Flanders-Belgium, France, Canada and USA. Informed
consent was obtained from all participants using proce-
dures approved by institutional review boards at each of
the clinical research centers enrolling subjects.
CLU resequencing
Unbiased resequencing was performed in the Flanders-
Belgian AD cohort by PCR sequencing of all 9 CLU
exons and their flanking intron-exon boundaries
[NM_001831.2], the 5’ and 3’UTR regions of longest
transcript 1 [NM_001831.2], the 5’UTR region of tran-
script 2 [NM_20339.1] and regulatory elements (Table 2
and see table in Additional file 1). Primers were
designed using ExonPrimer software and primer3. In
stages II and III, we performed targeted resequencing of
CLU exons 5-8 in the Lille, Toronto and Caribbean His-
panics AD cohorts (Table 3 Table 5). All sequences
were analyzed by two independent researchers using
Seqman, the NovoSNP software package [34] or Vector
NTI software (Invitrogen).
Statistical genetic analyses
Coding variant association
In stage I, an exon-by-exon approach was used to exam-
ine significance of putative clustering in AD patients of
rare CLU non-synonymous variants with a MAF of <
0.01-0.05 (Table 4). Alleles were collapsed and overall
frequency differences between AD patients and control
individuals were compared using c
2 statistics. Addition-
ally, we performed a literature search identifying in
PubMed all published studies that were reporting a
genetic screening of CLU in AD patients and healthy
individuals of Caucasian origin, yielding two publications
describing data in three AD cohorts from UK, Portugal
and US [14,15]. For the meta-analysis, we included all
rare coding variants predicting non-synonymous and
insertion/deletion mutations in the CLU b-chain
domain. Rare variant counts in patients and control
individuals were obtained for each dataset. To obtain
summary ORs and 95% CI, a fixed-effect (Mantel-
Haenszel) meta-analysis was performed in R using the
library rmeta-version 2.16.
Common SNP associations
The stage I Flanders-Belgian AD cohort (n = 1930,
Table 1) had an estimated power of 97% to detect a
modest association with an odds ratio (OR) of ~1.5 and
a common genetic variation with a minor allele fre-
quency (MAF) of 0.2 [35]. Tagging SNPs were selected
throughout the CLU locus (chr8:27.538.244 -
27.500.368; including 10 kb up- and downstream
regions), using the CEPH (Centre d’Etude du Poly-
morphism Humain) population of HapMap (Data Rel24/
phase II Nov08). SNPs with a MAF < 0.05, with a
Hardy-Weinberg equilibrium (HWE) p-value < 0.05 or
within repeat sequences (> 50%) were removed from the
selection. A total of 15 SNPs including the GWA top
SNP rs11136000 [2,3], were used in the stage I Flan-
ders-Belgian AD cohort for association analysis and for
fine-mapping of the association signal in the CLU locus
(See figure in Additional file 4).
Four SNPs were genotyped by sequencing (rs7982,
rs867230, rs3216167, rs11136000), the others SNPs by
Sequenom MassArray
® assay, followed by MALDI-TOF
mass spectrometry (Sequenom, Inc., Hamburg, Ger-
many). PCR and extension primers were designed using
Assay Design 3.1 Software. Genotypes were scored both
automatically (MassArray Typer version 4.0) and by two
researchers blind to disease status. Genotyping success
rate for SNPs genotyped with Sequenom was > 95%.
Inter-plate controls showed 100% concordance for all
genotyped SNPs. Deviations from HWE were deter-
mined using an exact HWE test [36].
For common SNPs, differences in allele frequencies
between AD patients and control individuals were tested
using c
2 statistics. P-values and odds ratios (OR) with
95% confidence intervals for the minor allele were calcu-
lated relative to the common allele and corrected for
gender, onset age or age at inclusion using binary logis-
tic regression models (Table 6a). Allelic associations
were further stratified for APOE status i.e. presence or
absence of APOE ε4 alleles (See table in additional file 3
and figure in Additional file 4). Statistical analyses were
performed using SPSS 16.0 (SPSS, Inc., Chicago, IL).
SNPs showing significant association at stage I, were
genotyped in the Lille and Toronto AD cohorts and
associations calculated (See table in Additional file 6).
Fixed-effect (Mantel-Haenszel) meta-analysis was per-
formed based on effect estimates of the separate cohorts
adjusted for age, gender and APOE ε4 status in R using
the library rmeta-version 2.16. Woolf’s test for heteroge-
neity was calculated. A Bonferroni p-value < 0.05, cor-
rected for the number of SNPs included in the meta-
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and see forest plots figure in Additional file 7).
Additional material
Additional file 1: Synonymous CLU variants and CLU variants in 3’
UTR, 5’ UTR, regulatory regions, and splice sites in Flanders-Belgian
AD cohort.
aGene location position according to the longest CLU
transcript with 9 coding exons [NM_001831.2],
bNumbering according to
build GRCh37/hg19 (Feb.2009), nucleotide changes given for
complementary negative strand; MAF = Minor Allele Frequency,
calculated upon the minimum number of successful sequences (1698 AD
alleles, 1318 control alleles) (B) The miRanda algorithm (microRNA
resource) was used to predict whether 3’ UTR variants are involved in
miRNA-binding [37]. TargetScan [38] and Pictar [39] were applied for
prediction of miRNA binding site positions. Polymorphisms in microRNA
Target Site (PolymiRTS) and Patrocles databases were used [40] to
estimate miRNA binding effects of variants. (D) Regulatory elements
(proximal promoter, OREG0018671) predicted using FirstEF and
OregAnno from UCSC browser Human Mar. 2006) were sequenced,
encompassing 458 nt before the translation initiation codon (transcript 1)
and 457 nt downstream of coding exon 1 [NM_001831.2]. No variants
were positions in conserved transcription factor binding sites (according
to UCSC). (E) Variants near splice sites. FSPLICE, Netgene2 and SPL were
used to predict possible splicing effects.
Additional file 2: Haplotype sharing of p.T445_D447del carriers.
Allele sharing of p.T445_D447del carriers (3 Belgian patients, 3 French
and 1 Canadian AD patient) was examined by genotyping 10 short
tandem repeat (STR) markers located in a 1.3 Mb region covering the
CLU locus.
aPhysical location of STR markers is relative to the NCBI
genome build 36, DNA of two unaffected children (with inclusion age <
50 years) of Belgian Flanders-Belgian carriers allowed reconstructing
haplotypes; Flanders-Belgian carriers of the insertion/deletion shared a
10-marker haplotype covering 1.3 Mb around CLU (shared alleles are
indicated in bold), two French patient carriers shared alleles at 7
consecutive markers of this haplotype, while French patient 2 and the
Canadian patient 1 only shared 3 consecutive markers with the Belgian
patients. Of note, Belgian insertion/deletion carriers also carried p.A309T
(Table 2), which was not detected in the French or Canadian individuals.
Additional file 3: Common CLU allelic associations in Flanders-
Belgian APOE ε4 strata.
aGene location position according to the
longest CLU transcript with 9 coding exons [NM_001831.2],
bNumbering
according to build GRCh37/hg19 (Feb.2009), minor alleles given for
complementary negative strand. Allele frequencies are shown with
absolute numbers in brackets. Calculations of odds ratios, presented with
95% confidence intervals (CI), were performed using the common allele
as reference allele. Nominal p-values were adjusted for age (onset age
for patients, inclusion age for control individuals) and gender in the
APOE subgroups. Nominally significant p-values are marked in bold.
Additional file 4: Schematic overview of CLU allelic associations and
LD pattern in Flanders-Belgian AD cohort. -log10 p-values for allelic
associations of 15 common SNPs (MAF > 0.05) encompassing the CLU
locus are given for the total cohort adjusted for age, gender and APOE,
and for APOE ε4 genotype strata adjusted for age and gender (Additional
file 3). Based upon 15 common SNP genotypes of stage I, the overall
linkage disequilibrium (LD) plot was reconstructed with D’ as LD measure
drawn using the LDheatmap v0.2-8 package. The LD pattern consisted of
a major LD block (12 consecutive SNPs starting from intron 3 to 3’
intergenic region) and a minor LD block of 3 SNPs upstream from CLU.
Additional file 5: Linkage disequilibrium measures in stage I and II
AD cohorts. Pairwise linkage measures (D’ and r
2) are given for the
associated SNPs in stage I and stage II cohorts.
Additional file 6: Common CLU allelic associations in replication AD
cohorts APOE ε4 strata. Allele frequencies are shown with absolute
numbers in brackets, minor alleles given for complementary negative
strand. Calculations of odds ratios, presented with 95% confidence
intervals (CI), were performed using the common allele as reference
allele. Nominal p-values were adjusted for age (onset age for patients,
inclusion age for control individuals) and gender in the APOE subgroups.
Nominally significant p-values are marked in bold.
Additional file 7: Forest plots of common CLU association in stage I
and II AD cohorts. Odds ratio’s and 95% confidence intervals are given
for stage I (Flanders-Belgian) and stage II cohorts (Lille, Toronto)
separately as well as overall combining stage I and II.
List of abbreviations
AA: Amino Acids; AD: Alzheimer’s disease; AAO: age at onset; AAI: age at
inclusion; CI: confidence interval; CLU: clusterin; GWA: genome-wide
association; HWE: Hardy-Weinberg equilibrium; MAF: minor allele frequency;
nt: nucleotides; OR: odds ratio; SD: standard deviation; SNP: single nucleotide
polymorphism; UTR: untranslated region.
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